No abstract

Background: Placenta Praevia (PP) is one a significant cause of maternal and perinatal morbidity and mortality. The aim of this study was to to determine the frequency maternal and neonatal outcomes among women with placenta previa. Methods: This cross-sectional study comprised all patients who had a cesarean section for PP at a tertiary referral hospital in Ahvaz, Islamic Republic of Iran, from May 2003 to December 2013. Maternal and neonatal data were obtained from the hospital database System at Obstetrics and Gynecology Department. diagnoses were confirmed during cesarean section. Results: In total, 87 patients with PP were evaluated. 29 patients had complete placenta previas, 33 partial, and 25 low lying placenta previa. 53 cases had previous cesarean sections. 33(37.9%) mothers had to admitted to the intensive care unit and 46(52.9%) mothers need to emergency cesarean. Mean postoperative hospital stay was 5.92 days. In total, 36.8% (n=32) of women underwent an obstetric hysterectomy. frequencies of bladder injuries were 6 (6.9%). postpartum hemorrhage in 37(42.5%) and 34(39.1%) patients were required blood transfusion. The mean packed red blood cell transfusion requirement was 4.4 units. There was no maternal death in this study. During the study period there were 81live births, 6 neonatal deaths, no still birth. Mean gestational age was 34.7 and Mean birth weight of the neonates was 2.5 kgs. There were 25 neonates with an APGAR score of less than 7. three (3.4%) babies were diagnosed as having RDS. 12 cases (13.8%) were diagnosed as small for gestational age and 2(2.2%) cases were IUGR. Conclusion: In our experience partial placenta previa was the most common type of PP. APGAR score <7, was the common neonatal complication and 46(52.9) need to emergency cesarean was the commonest maternal complications.

No abstract

Objective: This study was conducted to examine the histopathologic changes in tamoxifen-treated postmenopausal patients with endometrial thickness > 5 mm with transvaginal ultrasonography (TVS). Methods: Sixty two tamoxifen-treated postmenopausal breast cancer patients, receiving tamoxifen 20 mg/day for at least 1 year, underwent transvaginal pelvic ultrasonography followed by endometrial biopsy in case of an endometrial thickness > 5 mm. Ultrasonographic endometrial thickness and echotexture were recorded. Endometrial histopathologic findings were examined. Results: 55 patients were asymptomatic and 7 had abnormal bleeding. Overall, endometrial polyps were the most common histopathologic finding (42% of patients). A significant relation between ultrasonographic and histological findings was also documented (p < 0.05). A significant relation between histological findings and symptomatology was found (p < 0.05), although pathologies were also present in asymptomatic women. One endometrial cancer and three cases of hyperplasia were detected in patients with vaginal bleeding. Conclusions: Endometrial polyps are a frequent finding in tamoxifen-treated postmenopausal women with an endometrial thickness > 5 mm at transvaginal ultrasonography. Endometrial cystic atrophy may explain 'thickened endometrium' on transvaginal ultrasonography in group with no evidence of endometrial polyps, hyperplasia, or adenocarcinoma after surgical evaluation. The isolated use of TVS is insufficient for screening of endometrial hyperplasia or carcinoma in tamoxifen-treated postmenopausal women. OP19.09Comparison of endometrial thickness in OCP users and non OCP users M. Barati, F. Moramezi, N. Saadati, S. Masihi Ahvaz University of Medical Science, Islamic Republic of IranObjective: Specific cut-off levels of endometrial thickness in reproductive years women do not accurately defined. OCP suppress ovulation and endometrium is not under the effect of ovulation. In this study we tried to compare endometrial thickness in OCP users and non OCP users with transvaginal sonography. Methods: In this prospective study endometrial thickness of 83 women, 18 OCP users and 65 non OCP users were measured. These women had normal menstrual history and not having IUD. OCP users were at least in third months of OCP using and non OCP users were not using pills for at least three months. Menstrual cycle was divided to three phases, 7-10, 11-14, and 15-28 and endometrial thickness in these three phases were measured with transvaginal sonography. Results: Mean endometrial thickness in OCP and non OCP users were 2.52 and 8.97 mm respectively which had meaningful statistical difference, value < 0.001, with independent T-test and T equal to 8.18. Maximum and minimum endometrial thickness in OCP users was 4.40 and 1.00 mm respectively. Mean endometrial thickness in phase 1 to 3 in OCP users was 2.57, 2.67 and 2.68 mm and in non OCP users was 7.12, 9.04 and 10.07 mm respectively. Mean endometrial thickness in phase 1 and 3 of non OCP users had meaningful statistic...

Introduction:Registry data are critical in order to develop an understanding of the various features of rheumatic diseases, disease-specific outcomes and also the burden of diseases. The Khorasan territory registry for rheumatic diseases will be used to describe diseases and co-morbid illness, assesses disease outcomes and the consequences of the therapeutic interventions, and has potential for measuring the costs and its cost-effectiveness. Khorasan territory registry for rheumatic diseases was founded by the Rheumatic Diseases Research Center (RDRC) in 2015. The Khorasan Data Bank for rheumatic diseases is designed for various rheumatic diseases. It will be used principally to study individuals with Systemic Lupus Erythematous, Antiphospholipid Syndrome, Rheumatoid Arthritis, Poly-Dermatomyositis and other diseases. The main purpose of the rheumatic diseases registry is to design a system for systematic gathering, saving, analyzing and interpretation of data of patients with rheumatic diseases, and to further develop for prevention and treatment strategies in regards to planning the patients' care. Methods: Rheumatologist-written questionnaires have been developed to gather demographics, medical history, pregnancy history and outcomes, physical examinations as well as the patient's specific characteristics in accordance with their diagnosis of various rheumatic diseases and the treatment that each patient has received with regards to new biologics. It enrolls patients from the community who refer to rheumatology clinics at MUMS university hospitals, follows up with a validated key patient data set founded by the informatics center of MUMS. Rheumatologist-written data core make this longitudinal and ongoing registry available to statisticians for detailed analysis. Bio-banking will be our future mission. Results: So far, we have prepared the foundations and physical spaces and also, well organized questionnaires have been provided. Conclusion: Implementation of a well organized and funded registry are mandatory in our region in the north east of Iran for the prevention of the chaotic nature of the healthcare system and to provide well designed resources not simply for estimating the incidence of rheumatic diseases, but because it will also be a rich source of valid data for further studies. These data should be helpful in planning the delivery of rheumatology services not only in Mashhad-Khorasan, but also in the north east of Iran.